Skip to main content
Fig. 1 | Cost Effectiveness and Resource Allocation

Fig. 1

From: Pharmacoeconomic analysis of biologics and methotrexate for rheumatoid arthritis from the standpoint of the number needed to treat concept under the Japanese health insurance system

Fig. 1

Flowchart of patient enrollment in this study. In total, 905 consecutive patients newly presented to our hospital between 2012 and 2017. After excluding 756 patients, we enrolled and analyzed the remaining 149 RA patients. Patients divided into a bDMARDs group (55 patients), MTX group (66 patients), or control group (28 patients)

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us